<!doctype html><html lang=en-us><head><title>OMSF</title><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta name=description content="The Open Molecular Software Foundation"><meta name=author content><meta property="og:title" content="People"><meta property="og:description" content="Board of Directors  Brian Weitzner Director Linkedin | Web Outpace Bio
Dr. Brian Weitzner is the Director of Computational and Structural Biology at Outpace Bio, where he uses protein design to develop the next generation of cell-based immunotherapies for cancers. His research is focused on using and deepening our understanding of protein sequence–structure–function relationships to design novel proteins to address problems in human health. In addition to his scientific expertise, Brian brings experience with research software development and community building practices as an active contributor to Rosetta Commons and founding member of OpenFold."><meta property="og:type" content="article"><meta property="og:url" content="https://omsf.io/about/people/"><meta property="article:section" content="about"><meta name=twitter:card content="summary"><meta name=twitter:title content="People"><meta name=twitter:description content="Board of Directors  Brian Weitzner Director Linkedin | Web Outpace Bio
Dr. Brian Weitzner is the Director of Computational and Structural Biology at Outpace Bio, where he uses protein design to develop the next generation of cell-based immunotherapies for cancers. His research is focused on using and deepening our understanding of protein sequence–structure–function relationships to design novel proteins to address problems in human health. In addition to his scientific expertise, Brian brings experience with research software development and community building practices as an active contributor to Rosetta Commons and founding member of OpenFold."><meta name=generator content="Hugo 0.85.0"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/normalize/8.0.1/normalize.min.css integrity="sha256-l85OmPOjvil/SOvVt3HnSSjzF1TUMyT9eV0c2BzEGzU=" crossorigin=anonymous><link rel=stylesheet href=https://omsf.io/fontawesome/css/all.min.css><link rel=preconnect href=https://fonts.googleapis.com><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link href="https://fonts.googleapis.com/css2?family=Barlow:wght@400;600;700;900&display=swap" rel=stylesheet><link rel=stylesheet type=text/css href=/css/style.css><link rel=apple-touch-icon sizes=180x180 href=/apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=/favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=/favicon-16x16.png><link rel=manifest href=/site.webmanifest><meta name=msapplication-TileColor content="#da532c"><meta name=theme-color content="#ffffff"><script type=text/javascript>var _paq=window._paq=window._paq||[];_paq.push(['trackPageView']),_paq.push(['enableLinkTracking']),function(){var d="https://omsf.matomo.cloud/",b,a,c;_paq.push(['setTrackerUrl',d+'matomo.php']),_paq.push(['setSiteId','1']),b=document,a=b.createElement('script'),c=b.getElementsByTagName('script')[0],a.type='text/javascript',a.async=!0,a.src='//cdn.matomo.cloud/omsf.matomo.cloud/matomo.js',c.parentNode.insertBefore(a,c)}()</script></head><body><div id=container><header><a class=logo href=/><img src=/images/logo-web.png alt=OMSF></a><nav><ul><li><a class=active href=/about/mission>About</a></li><li><a href=/services/fiscal-sponsorship/>Services</a></li><li><a href=/projects/host-project>Projects</a></li><li><a href=https://news.omsf.io>News</a></li><li><a href=/support/how-to>Support</a></li></ul></nav><button onclick=myFunction() id=toggle-main-menu-mobile class="hamburger hamburger--slider" type=button>
<span class=hamburger-box><span class=hamburger-inner></span></span></button><div id=mobile-submenu style=display:none class=mobile-submenu><a class=active href=/about/mission>About</a>
<a href=/services/fiscal-sponsorship/>Services</a>
<a href=/projects/host-project>Projects</a>
<a href=https://news.omsf.io>News</a>
<a href=/support/how-to>Support</a></div><script>function myFunction(){var a=document.getElementById("mobile-submenu");a.style.display==="none"?a.style.display="block":a.style.display="none"}</script></header><main><div class=sub-wrapper><div class=sub><a href=/about/mission/><span>Mission</span></a>
<a class=active href=/about/people/><span>People</span></a>
<a href=/about/careers/><span>Careers</span></a>
<a href=/about/legal/><span>Documents</span></a></div></div><article><h1>People</h1><div class=header-two><img src=/OMSF/images/H2before.png alt><h2 id=board-of-directors>Board of Directors</h2></div><div class=image><p><img src=/images/brianweitzner.jpg.webp alt="Brian Weitzner">
<strong>Brian Weitzner</strong>
<em>Director</em>
<a href=https://www.linkedin.com/in/brian-weitzner>Linkedin</a> | <a href=https://weitzner.org/>Web</a>
<em>Outpace Bio</em></p><p>Dr. Brian Weitzner is the Director of Computational and Structural Biology at <a href=https://www.outpacebio.com/>Outpace Bio</a>, where he uses protein design to develop the next generation of cell-based immunotherapies for cancers. His research is focused on using and deepening our understanding of protein sequence–structure–function relationships to design novel proteins to address problems in human health. In addition to his scientific expertise, Brian brings experience with research software development and community building practices as an active contributor to <a href=https://www.rosettacommons.org/>Rosetta Commons</a> and founding member of <a href=https://openfold.io>OpenFold</a>.</p></div><div class=image><p><img src=/images/clarachrist.jpg alt="Clara Christ">
<strong>Clara Christ</strong>
<em>Director</em>
<a href=https://twitter.com/ClaraDChrist>Twitter</a> | <a href=https://de.linkedin.com/in/clara-christ-772874188>Linkedin</a>
<em>Bayer AG</em></p><p>Dr. Clara Christ is the Vice President, Head of Molecular Design at Bayer AG where her team focuses on advancing drug discovery projects with structural insights and digital means. She has worked as a computational chemist at Bayer AG since 2013 focusing on drug design in the therapy area oncology. Besides giving computational chemistry support in all stages of research projects she has been working on improving methods in the areas of de novo design, structure property analysis, and binding affinity prediction. Clara represents Bayer AG in the Open Free Energy Consortium.</p></div><div class=image><p><img src=/images/davidlmobley.jpg alt="David L. Mobley">
<strong>David L. Mobley</strong>
<em>President, Co-Founder</em>
<a href=https://twitter.com/davidlmobley>Twitter</a> | <a href=https://www.linkedin.com/in/david-mobley-1b09724>Linkedin</a> | <a href=https://mobleylab.org/>Web</a>
<em>University of California, Irvine</em></p><p>Prof. David Mobley holds a joint appointment in the Pharmaceutical Sciences and Department of Chemistry at the University of California, Irvine. A major focus of his research is the binding of small-molecule ligands to proteins, including development, application and validation of binding free energy methods. David is a strong proponent of open science and engaged in a series of community-driven projects and activities, such as spearheading the the <a href=https://www.samplchallenges.org/>SAMPL challenges</a> and co-leading the <a href=http://openforcefield.org/>Open Force Field Initiative</a>. He also serves on the editorial boards of several journals and is a founding and managing editor for the <a href=http://livecomsjournal.org/>Living Journal of Computational Molecular Science</a>. David co-founded OMSF and currently serves as the President of the OMSF Board of Directors.</p></div><div class=image><p><img src=/images/karmen.jpg alt="Karmen Condic-Jurkic">
<strong>Karmen Čondić-Jurkić</strong>
<em>Executive Director, Co-Founder</em>
<a href=http://twitter.com/karmecon>Twitter</a> | <a href=http://linkedin.com/in/karmen-condic-jurkic-805073b>LinkedIn</a>
<em>Open Molecular Software Foundation</em></p><p>Dr. Karmen Čondić-Jurkić is the co-founder and Executive Director of the Open Molecular Software Foundation. She also currently serves as the Board&rsquo;s Treasurer and Secretary. She has a background in computational chemistry. During her postdoc years, she developed a passion for open science and research infrastructure. She is particularly interested in collaboration and coordination of efforts, and how to make the research infrastructure more robust, sustainable and accessible. Karmen was the project manager for the <a href=http://openforcefield.org/>Open Force Field Initiative</a> before stepping into the role of OMSF Executive Director.</p></div><div class=image><p><img src=/images/michaelkgilson.jpg alt="Michael K. Gilson">
<strong>Michael K. Gilson</strong>
<em>Director</em>
<a href=http://twitter.com/michaelkgilson>Twitter</a> | <a href=http://linkedin.com/in/mkgilson>LinkedIn</a> | <a href=http://gilson.cloud.ucsd.edu/>Web</a>
<em>University of California, San Diego</em></p><p>Mike Gilson, MD, PhD, is Professor and Chair in Computer-Aided Drug Design at the <a href=https://pharmacy.ucsd.edu/>Skaggs School of Pharmacy and Pharmaceutical Sciences</a> and co-director of the <a href=http://drugdiscovery.ucsd.edu/>Center for Drug Discovery Innovation</a> at the <a href=https://ucsd.edu/>University of California San Diego</a>. He is also a member of the Executive Committee of the <a href=https://www.ucdrugdiscovery.org/>UC Drug Discovery Consortium</a>. A central theme of his research groups is advancing the technologies of computer-aided drug design (CADD), including protein-ligand binding thermodynamics, and force field development and validation. Mike has a long history of contributing to molecular sciences and following open science principles, including founding <a href=http://www.bindingdb.org/bind/index.jsp>BindingDB</a>, co-directing <a href=https://drugdesigndata.org/>Drug Design Data Resource</a> (D3R), and by holding community-wide, blinded prediction challenges. Mike is also one of the PIs leading the <a href=http://openforcefield.org/>Open Force Field Initiative</a> and serves on editorial boards of several journals.</p></div></article></main><footer class=footer-blue><div class="column-1 column"><img class=logo-footer src=/images/logo-white.png><p>Unless otherwise noted, all content is licensed under the <a style=text-decoration:underline href=https://creativecommons.org/licenses/by/4.0/>CC BY 4.0 license.</a></p></div><div class="column-2 column"><a href=/about/mission>About</a><br><a href=/services/fiscal-sponsorship/>Services</a><br><a href=/projects/host-project>Projects</a><br><a href=https://news.omsf.io>News</a><br><a href=/support/how-to>Support</a><br></div><div class="column-3 column"><a href=https://twitter.com/openmsf><img class=logo-footer src=/images/twitter-icon.png></a>
<a href=mailto:info@omsf.io><img class=logo-footer src=/images/mail-icon.png></a>
<a href=https://www.linkedin.com/company/><img class=logo-footer src=/images/linkedin-icon.png></a></div><div class="column-4 column"><a href=/privacy-policy>Privacy Policy</a><br><a href=/bylaws>Bylaws</a><br><a href=/good-standing-policy>Good Standing Policy</a><br><a href=/antitrust-policy>Antitrust Policy</a></div></footer></div></body></html>